China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership with Jilin Cancer Hospital. The collaboration is based on the hospital’s “Malignancy New Drug Creation Platform” and aims to bolster cancer drug development and accelerate BeiGene’s drug development activities. Financial details of the partnership were not disclosed.
Company Background
BeiGene boasts a rich and diversified product portfolio covering important targets such as TIGIT, BCL-2, and OX40. The company is currently conducting over 100 clinical studies across more than 45 countries and regions, with the majority being global multi-center clinical trials.-Fineline Info & Tech
